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Abstract 
Platelet activation at sites of vascular injury leads to the formation of a hemostatic plug and is 
crucial for hemostasis. However, uncontrolled platelet activation may lead to the formation of 
occlusive thrombi. Several soluble or matricellular proteins can activate platelets. In this 
article we review recent advances on the role of galectins in platelet physiology. Either in 
soluble or immobilized form, these endogenous glycan-binding proteins trigger platelet 
activation through modulation of discrete signaling pathways. We discuss the role of platelet-
galectin interactions not only in hemostasis, but also in chronic inflammation, atherosclerosis 
and cancer. 
Keywords: platelets, galectins, hemostasis, atherosclerosis, cancer, inflammation. 
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Introduction: platelets 
Platelets are anucleated cell fragments released from megakaryocytes. The primary role of 
platelets is to initiate and maintain haemostasis. However, their function is not limited to 
thrombosis, and extends into physiological processes such as tissue repair, wound remodeling 
and antimicrobial host defense, or pathologic processes such as atherosclerosis, chronic 
inflammation or cancer (Wagner 2005; Rivera, Lozano et al. 2009; Leslie 2010). In all these 
processes, platelets act as sentinels capable of responding rapidly to chemical changes in their 
environment.  
Under physiological conditions, platelets circulate in the blood in a quiescent state and their 
activation is inhibited by both, nitric oxide and prostacyclin released from endothelial cells. 
However, after vascular injury, platelets become activated and provide rapid protection 
against bleeding and catalyze the slower formation of stable blood clots via the coagulation 
cascade. In the initiation phase of primary hemostasis, platelets roll, adhere, and spread on the 
collagen matrix to form an activated platelet monolayer. During the rolling phase, adhesion is 
mediated mainly by the interaction between the glycoprotein (GP) Ib/V/IX receptor complex 
on the platelet surface with von Willebrand Factor (vWF), and between the GPVI and integrin 
IaIIa proteins with collagen present in the exposed subendothelium. These interactions allow 
the arrest and activation of adherent platelets. Platelet adhesion triggers the release of soluble 
mediators such as adenosine 5-diphosphate (ADP), thromboxane A2 (TXA2) and serotonin, 
which in combination with the locally generated thrombin, allow the formation of platelet-
platelet aggregates and the recruitment of additional circulating platelets which extend and 
stabilize the hemostatic plug. Specific interactions of these agonists with their G-protein 
coupled receptors generate inside-out signaling leading to the conformational activation of 
integrins, in particular αIIbβ3, increasing their ligand affinity (Angiolillo, Ueno et al. 2010). 
Binding of αIIbβ3 to its ligands, mainly fibrinogen, supports processes such as clot retraction, 
platelet aggregation and secretion of the granule proteins (Ma, Qin et al. 2007; Rivera, 
Lozano et al. 2009). Platelets contain four types of storage compartments – α-granules, dense 
granules, peroxisomes and lysosomes – whose contents are released into the circulation. 
When stimulated by thrombin, the platelet releasate contains > 300 proteins including 
prothrombotic substances, growth factors, chemokines and proteases. Although the release of 
cargo during exocytosis delivers many proteins into the circulation, the process also alters the 
composition of the platelet membrane, resulting in surface expression of P-selectin and an 
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increase in the number of integrin αIIbβ3 molecules (Nurden, Nurden et al. 2008). The 
exposure of P-selectin is especially important for platelet-leukocyte and platelet-endothelial 
interactions, as this molecule mediates the initial interactions of leukocytes and endothelium 
with activated platelets (Wagner 2005).  
The ability of platelets to store and release such a variety of bioactive mediators allows them 
to play an important role in modulating the function of other cells and explains why platelets 
are also critically involved in other biological processes beyond hemostasis. 
Galectins 
Galectins are evolutionarily-conserved lectins defined by at least one carbohydrate 
recognition domain (CRD) with affinity for β-galactosides and conserved sequence motifs. 
These lectins are found in almost all organisms and to date 15 galectins have been found in 
mammals; although only 12 galectin genes are found in humans. On the basis of their 
molecular structure, galectins are classified into three main types: ‘proto-type’ galectins, 
comprising a single polypeptide chain that is able to dimerize (galectin-1, -2, -5, -7, -10, -11,  
-13, -14, and -15); ‘tandem repeat-type’ galectins, composed of a single polypeptide chain 
presenting two CRDs connected by a linker peptide (galectin-4, -6, -8, -9, and -12); and the 
‘chimera-type’ galectin-3, which consists of one C-terminal CRD linked to an N-terminal 
peptide. A more recent classification based on gene sequence comparisons and intron–exon 
position analysis has classified galectins’ CRDs into two distinct subgroups (F3 and F4). 
Peculiarly, bi-CRD galectins usually display one domain of each type, F3 and F4 (Di Lella, 
Sundblad et al. 2011). Although most galectins bind N-acetyllactosamine [Galβ1-4-NAcGlc] 
units, important differences in glycan binding preferences among different members of the 
family have been reported (Rabinovich and Toscano 2009). Galectins function, either 
intracellularly or extracellularly, as key biological mediators capable of monitoring changes 
occurring on the cell surface during fundamental biological processes such as cellular 
communication, inflammation, wound healing, development, and differentiation. They also 
play unique roles in intracellular signaling pathways, regulation of RNA splicing, cell cycle 
control, and control of apoptotic signaling, endocytosis machinery, and trafficking (Di Lella, 
Sundblad et al. 2011). Galectins can influence the capacity of innate immune cells (e.g., 
neutrophils, dendritic cells, monocytes/macrophages, eosinophils, and mast cells) to respond 
to chemotactic gradients, migrate across endothelial cell surfaces, synthesize and release both 
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pro- and anti-inflammatory mediators, and recognize, engulf, and kill microbes and damaged 
cells. In this regard, similar to alarmins some members of the galectin family contribute to 
trigger innate immune responses, while others influence the resolution of acute inflammation. 
Besides, galectins can bind glycans on the surface of pathogenic microbes coupling 
recognition processes to innate immunity (Davicino, Elicabe et al. 2011). 
In spite of lack of a typical leader peptide required for secretion, galectins are released onto 
the extracellular milieu through an unusual, mostly unresolved mechanisms, where they play 
key roles as soluble mediators of various cell functions. In fact, galectins have been proposed 
to exert biological activities by forming supramolecular structures, termed ‘lattices’ with cell 
surface N-and O-glycans (Rabinovich, Toscano et al. 2007) 
Most galectins are expressed in a wide variety of tissues. While some galectins (e.g., galectin-1 
and -3) are widely expressed among different tissues of various species, other family 
members have a more restricted tissue localization and compartmentalization (e.g., galectin-7 
is preferentially found in the skin, galectin-12 abundantly expressed in adipose tissue, 
galectin-5 restricted to rat reticulocytes, and galectin-10 strongly represented in human 
eosinophils, where they play essential roles in the control of cell fate (Di Lella, Sundblad  
et al. 2011). 
Most galectins are overexpressed in several types of tumors and their expression correlates 
with tumor progression, aggressiveness and metastatic phenotype (Liu and Rabinovich 2005). 
For example, galectin-1 overexpression contributes to tumor immune escape, modulates 
tumor cell migration and adhesion and influences tumor angiogenesis (Thijssen, Postel et al. 
2006). High expression of galectin-8 is associated with malignancy in some type of tumors 
such as colon and lung and, preliminary studies showed that inhibition of galectin-8 promotes 
tumor regression (Bidon-Wagner and Le Pennec 2004).  
Platelet activation responses induced by galectin- 1 and -8 
Hemostasis and pathological thrombus formation are dynamic processes that require a co-
ordinated series of events involving platelet membrane receptors, bidirectional intracellular 
signals, and release of platelet proteins and inflammatory substances. Platelet activation can 
be triggered by a broad spectrum of vascular adhesive proteins such as vWF, collagen, 
fibronectin and soluble agonists including ADP, TXA2, thrombin and serotonin. (Rivera, 
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Lozano et al. 2009). It has been recently shown that two structurally different members of the 
galectin family of proteins, galectin-1 and 8 are potent platelet agonists (Pacienza, Pozner  
et al. 2008; Romaniuk, Tribulatti et al. 2010; Romaniuk, Croci et al. 2012). Through the 
interaction with the carbohydrate backbone of the major platelet receptors involved in 
hemostasis, e.g.: GPIbVIX complex and integrin αIIbβ3, both galectins are capable to induce 
all the myriad of platelet responses including adhesion and spreading, aggregation, release of 
their granule content and the expression of P-selectin on the platelet membrane (Pacienza, 
Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010; Romaniuk, Croci et al. 2012).  
Platelet receptors for galectin-1 and galectin 8 
Most of the extracellular functions mediated by galectins involve the interaction of these 
proteins with different cell surface glycoconjugates containing repeating units of  
N-acetyllactosamine [Galβ1,4GlcNAc] as well as extracellular matrix proteins. Among the 
different receptors, integrins are known to be involved in galectin-mediated biological 
responses (Rabinovich, Toscano et al. 2007). Platelet activation mediated by galectin-1 or 
galectin-8 is prevented by lactose but not by sucrose indicating the interaction of these lectins 
with specific carbohydrate ligands on the platelet surface. MALDI/TOF mass spectrometry 
analyses determined that both galectins binds the subunit αIIb from the αIIbβ3 integrin 
(Pacienza, Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). Additionally, while galectin-
8 also binds GPIb and V from GPIb-IX-V complex (Romaniuk, Tribulatti et al. 2010), 
galectin-1 interacts with α6β1. However, the use of platelets derived from patients who are 
deficient in αIIbβ3 or in GPIb, revealed that only GPIb and integrin αIIbβ3 are essential for 
galectin-8- and 1 dependent signal transduction respectively, and therefore represent 
functional counter-receptors (Romaniuk, Tribulatti et al. 2010; Romaniuk, Croci et al. 2012).  
Similar to other integrins, the function of platelet αIIbβ3 is regulated by inside-out or outside-
in signaling. Inside-out signaling occurs in response to binding of one or more platelet 
agonists and leads to the conversion of αIIbβ3 from a low-affinity/avidity receptor to a high-
affinity/avidity receptor, thereby allowing engagement of soluble multivalent adhesive 
ligands, such as fibrinogen and vWF. Ligand binding to the integrin triggers another cascade 
of signals known as outside-in, which leads to irreversible adhesion and aggregation (Ma, Qin 
et al. 2007). In this context, galectin-1 acts as a peculiar agonist as it is capable of triggering 
platelet activation through outside-in signaling via direct binding to αIIbβ3 integrin. This 
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intrinsic property of galectin-1 may be associated to a general feature of galectins, which has 
been proposed to form ordered arrays of supramolecular structures composed of multivalent 
glycans and lectins (often termed “lattices”) on the cell surface (Yang, Rabinovich et al. 
2008). Thus, it is conceivable that galectin-1 binding to αIIbβ3 integrin forms lattices that 
induce integrin clustering that leads to platelet signaling and activation.  
Signaling pathways involved in galectin-mediated platelet activation 
Although the model of how GPIb–GPIX–GPV signals in human platelets is currently 
incomplete, the activation of Src, PI3K, PLCγ 2 and ERK appears to be involved in GPIb 
activation mediated by vWF binding, its major ligand (Ozaki, Asazuma et al. 2005). In 
accordance with the notion that GPIb is an essential receptor for transducing galectin-8 
signaling, platelet stimulation by galectin-8 results in phosphorylation of PLCγ2, ERK1/2 and 
Akt. The phosphorylation of PLCγ2 and Akt appear to be relevant for platelet activation 
induced by galectin-8 since platelet aggregation is impaired in the presence of specific 
inhibitors of PLC and PI3K but not of MAPKK (Romaniuk, Tribulatti et al. 2010). 
Downstream signals involved in galectin-1 binding to platelets include the most common 
signals elicited by soluble or adhesive agonists that induce activation of αIIbβ3 integrin, such 
as Ca2+ mobilization and phosphorylation of PLCγ, Syk, mitogen-activated protein kinases 
(MAPKs), Akt, and β3 integrin. Tyrosine phosphorylation of the integrin tyrosine cytoplasmic 
motif of the β3 subunit is one of the most proximal and specific signaling events occurring 
after ligand binding to αIIbβ3 integrin and it is evident in vitro only under stirring conditions 
that allow integrin clustering or on platelet adhesion to immobilized fibrinogen (Ma, Qin et al. 
2007). Galectin-1-induced phosphorylation of β3 integrin occurs rapidly in addition of 
galectin-1 to platelet suspensions. Moreover, rapid tyrosine phosphorylation of Syk, PLCγ2, 
and Akt (signaling events involved in platelet outside-in signaling) was also observed after 
platelet exposure to soluble galectin-1 (Romaniuk, Croci et al. 2012). Interestingly, 
phosphorylation of these kinases has been described on platelet stimulation with concanavalin 
A, a plant lectin with different glycan specificity but similar conformation and topology that 
triggers platelet activation by inducing clustering of αIIbβ3 integrin molecules (Torti, Festetics 
et al. 1999). 
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Galectin-1 and galectin-8 trigger platelet aggregation  
The capacity of platelets to form a thrombus depends on their ability to aggregate. At the 
molecular level, platelet aggregation is mediated by a specific receptor on the platelet surface: 
the αIIbβ3 integrin (Rivera, Lozano et al. 2009). Like most traditional platelet agonists, both 
soluble galectin-1 and galectin-8 promote the transition of this integrin from a low-affinity 
state (resting state) to a high-affinity state (active state), which results in the unmasking of 
neoepitopes in the αIIbβ3 complex, and allows fibrinogen binding which acts as a bridging 
molecule between platelets to form aggregates. This conformational change of αIIbβ3 integrin 
triggered by galectins is accompanied by a raise in intracellular calcium levels as well as 
morphological changes of platelets involving the rearrangement of the cytoskeleton including 
extension of filopodia and lamellipodia (spreading) and F-actin polymerization (Pacienza, 
Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010).  
Both, galectin-1 and galectin-8 induce aggregation of platelets suspended either in plasma or 
buffer, which indicates a relevant role of these lectins in physiological media. Although cell 
agglutination was one of the first biological activities described for these lectins, this effect on 
platelets was only observed at high galectin-1 and galectin-8 concentrations. Platelet 
aggregation at lower concentrations is absent in fixed platelets, in the presence of calcium 
chelating agents, or eptifibatide (an αIIbβ3 antagonist), implying that platelet responses 
mediated by galectins could be related either to cell activation or to a clustering effect of platelet 
surface receptors depending on their concentration (Pacienza, Pozner et al. 2008; Romaniuk, 
Tribulatti et al. 2010). Although both galectins were capable of promoting aggregation, 
galectin-8 was found to be ten times more potent than galectin-1 in this stimulatory effect. 
Although the dimeric structure of galectin-8 would anticipate a more robust effect of this 
galectin compared to galectin-1, the observation that only the N-terminal domain was also able 
to trigger platelet activation indicates that lectin bivalency is not essential to promote activating 
effects on platelets. The differences in the concentration required to achieve a similar effect, 
could therefore reflect different downstream molecular signals triggered by each galectins 
(Romaniuk, Tribulatti et al. 2010; Romaniuk, Negrotto et al. 2011).  
The initial formation of platelet thrombus is rapidly reinforced by the generation and release 
of platelet TXA2 and ADP (the main metabolite of arachidonic acid by the cyclooxigenase 
pathway, and a component of platelet dense granules respectively) which acting in a paracrine 
and autocrine manner promote further platelet activation (Rivera, Lozano et al. 2009). Both 
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molecules are generated on platelet stimulation by galectin-1 and -8 (Pacienza, Pozner et al. 
2008; Romaniuk, Tribulatti et al. 2010). Moreover, although the aggregation response 
triggered by low galectin-8 concentrations was inhibited in the presence of aspirin 
(cyclooxigenase inhibitor) and/or an ADP-scavenger, a full response was obtained at higher 
concentrations indicating that galectin-8 is a strong agonist that activate platelets 
independently from TXA2 formation or ADP release (Pacienza, Pozner et al. 2008; 
Romaniuk, Tribulatti et al. 2010). 
Proinflammatory and procoagulant platelet-mediated responses 
induced by galectins 
The role of platelets in inflammation and vascular repair is mainly associated to the release of 
their alpha granule content, which includes among others, cell adhesion molecules that favor 
platelet/endothelial and leukocyte interaction, prothrombotic substances, and angiogenesis 
regulatory growth factors (May, Seizer et al. 2008; Etulain J 2012).  
Galectin-1 and -8 are strong inducers of P-selectin expression (Pacienza, Pozner et al. 2008; 
Romaniuk, Tribulatti et al. 2010). The major role of P-selectin on the platelet surface is the 
interaction with PSGL-1, its major counter-receptor on leukocytes, to form platelet-leukocyte 
aggregates (Wagner 2005). In fact, activation of platelets by galectin-1 in the presence of 
polymorphonuclear leukocytes results in a significant formation of heterotypic cell aggregates 
(Pacienza, Pozner et al. 2008). This interaction promotes activation of both cell types, which 
is a crucial condition for triggering inflammation, vascular remodeling and thrombosis. The 
expression of P-selectin on the platelet surface, the formation of leukocyte-platelets 
aggregates and leukocyte activation, are relevant events in acute syndromes including 
coronary diseases as well as in deep vein thrombosis (DVT) (Dotsenko, Chaturvedi et al. 
2007; Etulain J 2012). Given that galectins promote all these responses, binding of these 
lectins to platelets might represent potentially novel mechanism involved in both, arterial and 
venous thrombosis.  
In a cancer setting, the formation of heterotypic aggregates between circulating tumor cells 
overexpressing galectin-1 or -8 and platelets would result in P-selectin expression, which may 
contribute to the metastatic properties of these galectins by promoting stable adhesion to the 
endothelium and/or transmigration of tumor cells outside of the vasculature. 
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vWF is a large multimeric glycoprotein that allows platelet-endothelium, platelet-
subendothelium and platelet-platelet interaction and is therefore important for platelet 
adhesion and thrombus formation. Similarly to P-selectin, vWF is stored in platelet α-granules 
and in Weibel-Palade bodies of endothelial cells from which is released during injury or 
inflammation. vWF is a biomarker for endothelial dysfunction and cardiovascular risk and 
high levels of vWF are found in both chronic and acute inflammation (Luo, Ni et al. 2012). 
The release of vWF occurs after activation of platelets by galectin-1 (unpublished data) and -8 
(Romaniuk, Tribulatti et al. 2010). Thus, P-selectin expression and vWF release mediated by 
galectins might play an important role in the pathogenesis of thrombus formation and the 
modulation of inflammatory responses. 
While galectin-8 has been linked to proinflammatory processes (Cattaneo, Tribulatti et al. 
2011), both, anti and proinflammatory activities have been described for galectin-1 (Liu and 
Rabinovich 2010). Whether anti-inflammatory and pro-inflammatory effects occur at different 
concentrations of galectin-1 still remains to be established. The fact that galectin-1 promotes 
platelet activation support to the notion that under certain circumstances, galectin-1 could also 
act as a pro-inflammatory factor.  
Vesiculation of the platelet membrane and formation of platelet microparticles (PMPs) is a 
characteristic effect of certain agonists such as collagen, thrombin or C5b-9 complement 
fragment. PMPs are released not only during platelet activation in vitro but are also detected 
in vivo (Morel, Toti et al. 2006). They are thought to provide catalytic surface for several 
enzyme complexes of the coagulation system and to underlie the pro-coagulant responses 
elicited by platelet activation. Moreover, PMPs may themselves evoke cellular responses in 
the immediate microenvironment including platelet adhesion to the site of endothelial injury 
and angiogenesis. The ability of galectin-1 to induce phosphatidylserine-expressing PMPs 
(Pacienza, Pozner et al. 2008) suggests that this lectin not only promotes platelet activation, 
but could also indirectly activates the coagulation cascade. 
Galectins and platelet adhesion  
Platelet adhesion and spreading, together with cytoskeletal rearrangements, are early 
functional responses that occur upon vascular injury as a consequence of outside-in signaling 
on ligand binding to αIIbβ3 and integrin oligomerization (Rivera, Lozano et al. 2009). Platelet 
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adhesion to the extracellular matrix at sites of vascular injury represents a key step for 
limiting bleeding but, if uncontrolled, can lead to occlusion. Immobilized galectin-1 and -8 
are efficient substrates for platelet adhesion, filopodia, and lamellipodia formation in the 
absence of additional platelet agonists (Pacienza, Pozner et al. 2008; Romaniuk, Croci et al. 
2012). The demonstration that immobilized galectins are as efficient as their soluble form in 
triggering platelet activation together with the observation that their expression is increased in 
activated endothelium or tumor cells (Thijssen, Hulsmans et al. 2008), suggest that the 
interaction of platelets with immobilized galectin-1 or -8 could be relevant in different clinical 
settings, including not only vascular but also inflammatory disorders such as atherosclerosis 
and cancer. Several studies demonstrated that galectins including galectin-1 and -8 participate 
in the initiation, progression and rupture of an atheroma plaque (Al-Ansari, Zeebregts et al. 
2009). Galectins expressed in the inner of atheroma plaque, may not only influence platelet 
activation but may also serve as key components of the extremely thrombogenic core exposed 
after plaque rupture, the main trigger for acute thrombus formation and the cause of unstable 
angina, myocardial infarction, transient ischemic attack and stroke (May, Seizer et al. 2008).  
In cancer, platelets are known to contribute to tumor progression and metastasis. One of the 
mechanisms underlying this effect is the formation of mixed-cell aggregates between tumor 
cells expressing mucins and platelets expressing P-selectin; these complexes prevent tumor 
cell attack by the immune system (Leslie 2010). In the same line of evidence, the interaction 
between tumor cells expressing high levels of galectins and platelets could represent another 
molecular mechanism through which both, platelets and galectins promote the metastatic 
cascade. Interestingly and in contrast to mucin-P-selectin interactions, the interaction of tumor 
cells with platelets via galectins would not require the presence of activated platelets. 
Furthermore, the overexpression of galectins in tumor cells could also represent a trigger for 
platelet activation allowing the release of α-granules content including growth factors, which 
can promote tumor progression and angiogenesis. 
Platelets express galectin-1 and galectin-8 
In addition to vascular cells, human platelets express substantial levels of galectin-1 and -8 
(Pacienza, Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). Although both galectins are 
secreted proteins, they are mainly found in the cytosol of different cell types. Human platelets 
express the two splice variants of galectin-8. Moreover, whereas galectin-8, like P-selectin, is 
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absent on the surface of resting platelets, it is exposed on the membrane of thrombin-
stimulated platelets (Romaniuk, Tribulatti et al. 2010). This finding suggests that in the 
vascular system, platelets are another source of galectin-8 that would be accessible upon 
platelet activation to eventually promote thrombus growth. Furthermore, it has been recently 
shown that galectin-8 regulates platelet function by mediating the uptake of platelet proteins 
(i.e. FV) by megakaryocytes (Zappelli, van der Zwaan et al. 2012). In contrast, galectin-1 is 
not expressed on the platelet surface upon activation (unpublished observations). The 
differences between both galectins are still not clear. Interestingly, addition of lactose and 
thiodigalactoside partially prevents aggregation induced by classical agonists suggesting that 
platelet-derived galectins and their glycans might contribute to platelet activation.  
Thrombosis and disseminated intravascular coagulation are common complications in cancer 
patients. A hypercoagulable or pro-thrombotic state of malignancy occurs due to the ability of 
tumor cells to activate platelets and the coagulation system. Pro-thrombotic factors in cancer 
include the ability of tumor cells to produce and secrete pro-coagulant/fibrinolitic substances 
and pro-inflammatory cytokines and the physical interaction between tumor cells and 
platelets. However, the mechanisms allowing the occurrence of prothrombotic states in cancer 
patients are not completely understood.  
The observed increased of galectin-1 and -8 in tumoral endothelial cells as well as in other 
malignant cells could represent a pathogenic mechanism involved in thrombosis and 
disseminated intravascular coagulation complications. Given the pivotal role of galectin-1 and 
-8 in tumor progression, it could be conceivable that galectin-induced platelet activation might 
contribute to the pathogenesis of thrombosis in cancer patients 
Galectin-1 plays a role in normal primary hemostasis 
The relevance of galectin-1 in hemostasis, has been recently studied in galectin-1 null mutant 
mice. Animals deficient in galectin-1 had prolonged bleeding time, an effect which was not 
associated with a decrease in platelet number but rather to a platelet dysfunction. In fact, 
galectin-1-deficient platelets showed a restricted adhesion to immobilized fibrinogen and a 
delayed clot retraction, two platelet activation responses dependent on outside-in signaling of 
platelet integrin αIIbβ3 (Romaniuk, Croci et al. 2012). Thus, an impairment of this activation 
pathway appears to be a major cause of the altered bleeding time in mice lacking galectin-1. 
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Interestingly, many of the hemostatic alterations present in mice with galectin-1 ablation 
recapitulate the phenotypes observed in mice devoid of the tetraspanin superfamily member 
TSSC6 or in mice in which the integrin cytoplasmic tyrosine motif has been mutated to 
phenylalanine, which all exhibited impaired outside-in signaling (Romaniuk, Croci et al. 
2012). The concept that galectin-1 has a role in hemostasis was also recently described by 
Saint-Lu N et al. who showed that galectin-1/galectin-3 double-deficient mice are 
characterized by a more rapid formation of initial thrombi following ferric chloride–induced 
injury, but less stable occlusive thrombi compared with those of wild-type mice(Saint-Lu, 
Oortwijn et al. 2012). 
Conclusions 
Over the last decade we have witnessed significant advances regarding the biology of 
galectins and their role in cellular homeostasis: Particularly considerable progress has been 
made on the contribution of galectins to innate and adaptive immune responses.The 
information currently available indicates that galectins are expressed and secreted by several 
cell types in normal and pathologic conditions.The emerging evidence showing that galectins 
are also capable of triggering platelet activation opens a completely new field of research 
where so far there are more questions than answers. From a more general perspective, this 
field will also uncover the role of glycans and glycosyltransferases in platelet function and 
hemostasis. The study of galectin-glycan interactions in platelet activation will provide further 
insight into the mechanisms linking inflammatory mediators to thrombus formation and could 
expand our view of the role of platelets much beyond homeostasis to their pathophysiologic 
role during inflammation and cancer. 
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